<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387178</url>
  </required_header>
  <id_info>
    <org_study_id>111267</org_study_id>
    <nct_id>NCT01387178</nct_id>
  </id_info>
  <brief_title>Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation
      caused by inflammation-mediated damage to lung tissue. Although damage to lung tissue in COPD
      appears to be irreversible, evidence suggests that the course of COPD can be altered through
      measures such as smoking cessation, pulmonary rehabilitation, and the use of pharmacotherapy
      for bronchodilation. A primary goal of maintenance pharmacotherapy is to reduce the incidence
      of acute exacerbations and the associated hospitalizations and emergency department (ED)
      visits. Bronchodilation in COPD maintenance therapy can be accomplished with the long-acting
      anticholinergic tiotropium (TIO), long acting beta-agonists (e.g. formoterol, salmeterol),
      methylxanthines (e.g. theophylline), or combination therapy with a long-acting beta-agonist
      and an inhaled corticosteroid (e.g. fluticasone propionate/salmeterol [FSC]).

      The objective of this study is to compare the benefits of combination long-acting
      beta-agonist/inhaled corticosteroid therapy to long-acting anticholinergic therapy. The study
      compares the risk of COPD exacerbations and COPD-related healthcare utilization and costs for
      commercially-insured patients age 40 and older who were prescribed FSC to those prescribed
      TIO. The null hypothesis is that no difference exists between the costs and outcomes of COPD
      patients treated with TIO and those treated with FSC. The test hypothesis is that patients
      treated with either TIO or FSC will incur lower costs and use fewer healthcare resources for
      the management of COPD.

      The source of data for this study was the Ingenix Impact database (formerly the Integrated
      Healthcare Information Services [IHCIS] database). This is an administrative claims database
      that includes patient-level data on enrollment, facility, professional, and pharmacy services
      from approximately 50 million patients covered by more than 40 managed care health plans
      across the United States (US).

      The study design is a retrospective cohort study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-index Period COPD-related, Unadjusted Costs</measure>
    <time_frame>1 year</time_frame>
    <description>The mean cost per participant for COPD-related healthcare interventions for one year following the index date (first pharmacy claim for fluticasone propionate/salmeterol 250 µg/50 µg [FSC] or tiotropium bromide [TIO]) was calculated. Total medical costs included inpatient, emergency department, and outpatient costs associated with the treatment of COPD. Total pharmacy costs included costs of all COPD-related medications, and total healthcare costs included all medical and pharmacy costs that were related to COPD treatment. These costs were unadjusted and reflect the actual costs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Number of COPD Exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>Moderate COPD exacerbations were defined as the occurrence of a COPD-related emergency department (ED) visit or a COPD-related office visit that is closely followed by a prescription claim for oral steroids or antibiotics. Severe exacerbations were defined as the occurrence of a COPD-related hospital admission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of COPD-related Healthcare Encounters</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">22223</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>COPD patients - risk analysis population</arm_group_label>
    <description>Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. Patient records for the risk analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 3 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and June 30, 2008).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients - cost analysis population</arm_group_label>
    <description>Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. The cost analysis population is a subset of the risk analysis population. Patient records for the cost analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 12 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and September 30, 2007).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate/salmeterol 250µg/50µg (FSC)</intervention_name>
    <description>Patient records with evidence of COPD and prescription claims for FSC</description>
    <arm_group_label>COPD patients - cost analysis population</arm_group_label>
    <arm_group_label>COPD patients - risk analysis population</arm_group_label>
    <other_name>Advair®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide (TIO)</intervention_name>
    <description>Patient records with evidence of COPD and prescription claims for TIO</description>
    <arm_group_label>COPD patients - cost analysis population</arm_group_label>
    <arm_group_label>COPD patients - risk analysis population</arm_group_label>
    <other_name>Spriva®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient records for commercially-insured patients with chronic obstructive pulmonary
        disease (COPD) aged 40 and older. For the risk-analysis population, patients were required
        to have at least 12 months of continuous enrollment prior to the index date and at least 3
        months of continuous enrollment after the index date. A subgroup analysis was conducted for
        costs that included patients in the total population who also had at least 12 months of
        continuous coverage following the index date (the cost-analysis population).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is age 40 or older

          -  Patient record indicates a new prescription claim for fluticasone
             propionate/salmeterol (FSC) or tiotropium bromide (TIO) (first pharmacy claim defines
             the index date)

          -  Patient records include at least two medical claims with a primary or non-primary
             diagnosis of COPD (International Classification of Disease-9 [ICD-9] code 490.xx -
             492.xx or 496.xx)

          -  At least one of the patient's ICD-9 codes for COPD is observed in the 12 months prior
             to the first pharmacy claim for FSC or TIO (the index date)

        Exclusion Criteria:

          -  A pharmacy claim for FSC or TIO prior to the index date

          -  The patient initiated FSC at a dose other than 250µg/50µg

          -  The patient initiated FSC and TIO at the same time

          -  The patient had one or more prescription with missing dosing information

          -  The patient had a prescription claim for the study medication other than the one they
             started on at the index date within 60 days after the index date
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2011</study_first_posted>
  <results_first_submitted>September 21, 2011</results_first_submitted>
  <results_first_submitted_qc>September 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2011</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>cost and cost analysis</keyword>
  <keyword>bronchodilators</keyword>
  <keyword>healthcare utilization</keyword>
  <keyword>fluticasone propionate/salmeterol</keyword>
  <keyword>tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymized and used to develop a cohort. All diagnoses and treatments are recorded in the course of routine medical practice.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone Propionate/Salmeterol 250 Micrograms (µg)/50 µg</title>
          <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (International Classification of Disease, 9th Edition, Clinical Modification [ICD-9-CM] code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for fluticasone/propionate 250 µg /50 µg (FSC)</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium Bromide 18 µg</title>
          <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for tiotropium bromide (TIO)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11582"/>
                <participants group_id="P2" count="10641"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11582"/>
                <participants group_id="P2" count="10641"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone Propionate/Salmeterol 250 Micrograms (µg)/50 µg</title>
          <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for FSC</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium Bromide 18 µg</title>
          <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for TIO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11582"/>
            <count group_id="B2" value="10641"/>
            <count group_id="B3" value="22223"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="10.6"/>
                    <measurement group_id="B2" value="63.1" spread="10.0"/>
                    <measurement group_id="B3" value="61.9" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6121"/>
                    <measurement group_id="B2" value="4958"/>
                    <measurement group_id="B3" value="11079"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5461"/>
                    <measurement group_id="B2" value="5683"/>
                    <measurement group_id="B3" value="11144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Some participants are grouped into the “National” region to protect their identities because the combination of their medical and demographic information is considered “infrequent” and could potentially be used to identify the participants.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Northeast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4523"/>
                    <measurement group_id="B2" value="4149"/>
                    <measurement group_id="B3" value="8672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3818"/>
                    <measurement group_id="B2" value="3630"/>
                    <measurement group_id="B3" value="7448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Midwest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1790"/>
                    <measurement group_id="B2" value="1731"/>
                    <measurement group_id="B3" value="3521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1085"/>
                    <measurement group_id="B2" value="827"/>
                    <measurement group_id="B3" value="1912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>National or Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="366"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated payer source</title>
          <description>Participants were classified according to the type of healthcare payer with which they were associated.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Commercial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10233"/>
                    <measurement group_id="B2" value="9227"/>
                    <measurement group_id="B3" value="19460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicaid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicare</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1228"/>
                    <measurement group_id="B2" value="1364"/>
                    <measurement group_id="B3" value="2592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Charlson Comorbidity Score</title>
          <description>The Charlson Comorbidity Index estimates 10-year mortality risk. Scores range from 0 - 37, with a lower score indicating a higher chance of survival.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="2.1"/>
                    <measurement group_id="B2" value="1.6" spread="2.2"/>
                    <measurement group_id="B3" value="1.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of the Indicated Pre-Index Period COPD-related comorbidities</title>
          <description>The pre-index period was defined as the 12 months prior to the index date, which corresponded with the start of the study medication.</description>
          <units>number of comorbidities</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3326"/>
                    <measurement group_id="B2" value="1651"/>
                    <measurement group_id="B3" value="4977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1472"/>
                    <measurement group_id="B2" value="1624"/>
                    <measurement group_id="B3" value="3096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4395"/>
                    <measurement group_id="B2" value="2952"/>
                    <measurement group_id="B3" value="7347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower respiratory infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="531"/>
                    <measurement group_id="B2" value="475"/>
                    <measurement group_id="B3" value="1006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of the Indicated Pre-Index Period Treatments</title>
          <units>number of treatments</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Long-acting beta-agonist use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="556"/>
                    <measurement group_id="B3" value="798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxygen use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1210"/>
                    <measurement group_id="B2" value="1517"/>
                    <measurement group_id="B3" value="2727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with the Indicated COPD Severity</title>
          <description>Mild, moderate, and severe COPD were defined by an algorithm for retrospective data analyses that is based on COPD-related healthcare encounters such as intensive care unit stays, hospitalizations, emergency department/urgent care visits, and the use of oxygen.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9442"/>
                    <measurement group_id="B2" value="8476"/>
                    <measurement group_id="B3" value="17918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="750"/>
                    <measurement group_id="B2" value="520"/>
                    <measurement group_id="B3" value="1270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1390"/>
                    <measurement group_id="B2" value="1645"/>
                    <measurement group_id="B3" value="3035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-index Period COPD-related, Unadjusted Costs</title>
        <description>The mean cost per participant for COPD-related healthcare interventions for one year following the index date (first pharmacy claim for fluticasone propionate/salmeterol 250 µg/50 µg [FSC] or tiotropium bromide [TIO]) was calculated. Total medical costs included inpatient, emergency department, and outpatient costs associated with the treatment of COPD. Total pharmacy costs included costs of all COPD-related medications, and total healthcare costs included all medical and pharmacy costs that were related to COPD treatment. These costs were unadjusted and reflect the actual costs.</description>
        <time_frame>1 year</time_frame>
        <population>A subpopulation of participants with an index date between January 1, 2004 and September 30, 2007</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Propionate/Salmeterol 250 Micrograms (µg)/50 µg</title>
            <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for FSC</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide 18 µg</title>
            <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for TIO</description>
          </group>
        </group_list>
        <measure>
          <title>Post-index Period COPD-related, Unadjusted Costs</title>
          <description>The mean cost per participant for COPD-related healthcare interventions for one year following the index date (first pharmacy claim for fluticasone propionate/salmeterol 250 µg/50 µg [FSC] or tiotropium bromide [TIO]) was calculated. Total medical costs included inpatient, emergency department, and outpatient costs associated with the treatment of COPD. Total pharmacy costs included costs of all COPD-related medications, and total healthcare costs included all medical and pharmacy costs that were related to COPD treatment. These costs were unadjusted and reflect the actual costs.</description>
          <population>A subpopulation of participants with an index date between January 1, 2004 and September 30, 2007</population>
          <units>United States (US) dollars</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7933"/>
                <count group_id="O2" value="6372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inpatient services</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="688" spread="4998"/>
                    <measurement group_id="O2" value="867" spread="6887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency department visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="415"/>
                    <measurement group_id="O2" value="52" spread="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inpatient and emergency department visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="743" spread="5090"/>
                    <measurement group_id="O2" value="919" spread="6977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Office visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" spread="388"/>
                    <measurement group_id="O2" value="293" spread="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other outpatient/ancillary services</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="734" spread="2504"/>
                    <measurement group_id="O2" value="879" spread="3050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total medical costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1709" spread="6322"/>
                    <measurement group_id="O2" value="2091" spread="8302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total pharmacy costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1291" spread="1791"/>
                    <measurement group_id="O2" value="1209" spread="1378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total healthcare utilization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3000" spread="6805"/>
                    <measurement group_id="O2" value="3299" spread="8536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>7451</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5857</ci_lower_limit>
            <ci_upper_limit>9045</ci_upper_limit>
            <estimate_desc>The mean predicted cost for inpatient services for participants treated with FSC. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>11545</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8827</ci_lower_limit>
            <ci_upper_limit>14263</ci_upper_limit>
            <estimate_desc>The mean predicted cost for inpatient services for participants treated with TIO. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58</ci_lower_limit>
            <ci_upper_limit>63</ci_upper_limit>
            <estimate_desc>The mean predicted cost for emergency department visits for participants treated with FSC. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49</ci_lower_limit>
            <ci_upper_limit>53</ci_upper_limit>
            <estimate_desc>The mean predicted cost for emergency department visits for participants treated with TIO. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>231</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>227</ci_lower_limit>
            <ci_upper_limit>234</ci_upper_limit>
            <estimate_desc>The mean predicted cost for office visits for participants treated with FSC. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>295</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>290</ci_lower_limit>
            <ci_upper_limit>299</ci_upper_limit>
            <estimate_desc>The mean predicted cost for office visits for participants treated with TIO. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>873</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>827</ci_lower_limit>
            <ci_upper_limit>919</ci_upper_limit>
            <estimate_desc>The mean predicted cost for other outpatient and ancillary services for FSC participants. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>1080</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1022</ci_lower_limit>
            <ci_upper_limit>1138</ci_upper_limit>
            <estimate_desc>The mean predicted cost for other outpatient and ancillary services for TIO participants. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>1267</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1251</ci_lower_limit>
            <ci_upper_limit>1283</ci_upper_limit>
            <estimate_desc>The mean predicted cost for pharmacy services for participants treated with FSC. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>1250</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1234</ci_lower_limit>
            <ci_upper_limit>1266</ci_upper_limit>
            <estimate_desc>The mean predicted cost for pharmacy services for participants treated with TIO. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>1175</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1083</ci_lower_limit>
            <ci_upper_limit>1267</ci_upper_limit>
            <estimate_desc>The mean predicted cost for inpatient and emergency department services for FSC participants. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>1566</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1438</ci_lower_limit>
            <ci_upper_limit>1695</ci_upper_limit>
            <estimate_desc>The mean predicted cost for inpatient and emergency department services for TIO participants. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>2991</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2922</ci_lower_limit>
            <ci_upper_limit>3059</ci_upper_limit>
            <estimate_desc>The mean predicted cost for total healthcare services for participants treated with FSC. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Mean</param_type>
            <param_value>3304</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3221</ci_lower_limit>
            <ci_upper_limit>3386</ci_upper_limit>
            <estimate_desc>The mean predicted cost for total healthcare services for participants treated with TIO. A generalized linear model with a log link function and gamma distribution for the error term to resolve the issue of skewed cost distribution was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of COPD Exacerbations</title>
        <description>Moderate COPD exacerbations were defined as the occurrence of a COPD-related emergency department (ED) visit or a COPD-related office visit that is closely followed by a prescription claim for oral steroids or antibiotics. Severe exacerbations were defined as the occurrence of a COPD-related hospital admission.</description>
        <time_frame>1 year</time_frame>
        <population>The total population including participants with index dates between January 1,2004 and June 30, 2008.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Propionate/Salmeterol 250 Micrograms (µg)/50 µg</title>
            <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for FSC</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide 18 µg</title>
            <description>Participants 40 years of age or older with &amp;gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &amp;gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &amp;gt;=1 in the post-index date observation period, and &amp;gt;=1 prescription claim for TIO</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of COPD Exacerbations</title>
          <description>Moderate COPD exacerbations were defined as the occurrence of a COPD-related emergency department (ED) visit or a COPD-related office visit that is closely followed by a prescription claim for oral steroids or antibiotics. Severe exacerbations were defined as the occurrence of a COPD-related hospital admission.</description>
          <population>The total population including participants with index dates between January 1,2004 and June 30, 2008.</population>
          <units>number of exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11582"/>
                <count group_id="O2" value="10641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.77"/>
                    <measurement group_id="O2" value="0.29" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.29"/>
                    <measurement group_id="O2" value="0.05" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.87"/>
                    <measurement group_id="O2" value="0.34" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2198</p_value>
            <p_value_desc>Risk of Moderate COPD Exacerbations</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.964</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.909</ci_lower_limit>
            <ci_upper_limit>1.022</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0406</p_value>
            <p_value_desc>Risk of Severe COPD Exacerbations</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.864</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.752</ci_lower_limit>
            <ci_upper_limit>0.994</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0962</p_value>
            <p_value_desc>Risk of Any COPD Exacerbation</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.953</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.901</ci_lower_limit>
            <ci_upper_limit>1.009</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD-related Healthcare Encounters</title>
        <time_frame>1 year</time_frame>
        <population>A subpopulation of participants with an index date between January 1, 2004 and September 30, 2007</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Propionate/Salmeterol 250 Micrograms (µg)/50 µg</title>
            <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for FSC</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide 18 µg</title>
            <description>Participants 40 years of age or older with &amp;gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &amp;gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &amp;gt;=1 in the post-index date observation period, and &amp;gt;=1 prescription claim for TIO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD-related Healthcare Encounters</title>
          <population>A subpopulation of participants with an index date between January 1, 2004 and September 30, 2007</population>
          <units>number of encounters</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7933"/>
                <count group_id="O2" value="6372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inpatient services</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2155"/>
                    <measurement group_id="O2" value="1792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emergency department visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3085"/>
                    <measurement group_id="O2" value="2312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inpatient and emergency department visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3673"/>
                    <measurement group_id="O2" value="2817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Office visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7833"/>
                    <measurement group_id="O2" value="6295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other outpatient/ancillary services</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7243"/>
                    <measurement group_id="O2" value="5859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone Propionate/Salmeterol 250 Micrograms (µg)/50 µg</title>
          <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for FSC</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium Bromide 18 µg</title>
          <description>Participants 40 years of age or older with &gt;=2 medical claims with a primary or non-primary diagnosis of COPD (ICD-9-CM code 490.xx, 491.xx, 492.xx, or 496.xx), &gt;=1 in the 12 months prior to the index date (defined as the first pharmacy claim for the study drug), &gt;=1 in the post-index date observation period, and &gt;=1 prescription claim for TIO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

